ArticleBiomaterials research2026
Bionic Nanoparticle Hydrogel for Astrocyte-Targeted Estradiol Delivery Ameliorates Perimenopausal Depression via P2X7 Receptor Inhibition.
Article in Biomaterials research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanomedicine for Depression: From Blood-Brain Barrier Delivery to Neuroimmune-Barrier-Plasticity Network Reprogramming.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Estrogen (E2) therapy has shown efficacy in alleviating perimenopausal depression but is often accompanied by adverse effects when administered systemically. In this study, we developed a biomimetic nanoliposome hydrogel nasal delivery system for targeted E2 delivery and investigated its mechanisms. The system was constructed using aminated mesoporous silica as a carrier to load E2, followed by coating with astrocyte cell membranes to achieve targeting capability. The resulting nanoparticles were then embedded in a thermosensitive hydrogel composed of carboxymethyl chitosan and Pluronic F127, forming a nasal delivery platform (AEC@CP) for efficient brain targeting. A perimenopausal depression mouse model (OVX-CUMS) was established to evaluate E2's effects on depressive behavior, hippocampal pyroptosis, and the P2X7 receptor (P2X7R)/NLRP3/caspase-1/gasdermin (GSDMD) pathway. In vitro, primary astrocytes were induced with lipopolysaccharide-adenosine triphosphate to construct a P2X7R overexpression model. AEC@CP was characterized and tested for therapeutic efficacy both in vitro and in vivo. Results showed that OVX-CUMS mice exhibited elevated astrocytic pyroptosis, which was attenuated by E2. E2 down-regulated interleukin-18 (IL-18) and IL-1β in the hippocampus and inhibited P2X7R/NLRP3/caspase-1/GSDMD signaling. In vitro, E2 suppressed astrocytic pyroptosis and associated pathway activation, and P2X7R overexpression reversed these effects. AEC@CP demonstrated excellent targeting and cellular uptake, and exerted stronger antidepressant and anti-pyroptotic effects than did free E2. In conclusion, AEC@CP effectively delivers E2 to astrocytes, suppressing the P2X7R-mediated inflammasome pathway, reducing pyroptosis, and improving depressive behavior in perimenopausal mice.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.